Building Your Care Team and Long-Term Monitoring
At a Glance
Alpha-mannosidosis can affect several body systems, so long-term care is coordinated by a metabolic geneticist and other specialists. Personalized monitoring may cover hearing, vision, heart and lung health, development, mental health, and a planned transition to adult care.
Managing alpha-mannosidosis is not something one doctor can do alone. Because the condition affects multiple systems—from hearing and bone health to the immune system and the brain—it requires a “multidisciplinary” care team [1]. This team works together to monitor health, coordinate therapies, and adjust treatments over a lifetime.
Your Care Team Roster
A specialized metabolic geneticist or biochemical geneticist usually leads medical care [1]. However, daily functioning depends heavily on a broader team:
- Genetic Counselor: To discuss family recurrence risks and reproductive options.
- Audiologist and ENT: To monitor and manage hearing loss (sensorineural or conductive) and ear infections [2][3].
- Physical, Occupational, and Speech-Language Therapists: To maximize mobility, daily living skills, and communication.
- Neurologist: To track brain health, motor skills, and ataxia [4].
- Ophthalmologist: To monitor the retina and optic nerve [5].
- Pulmonologist and Cardiologist: To evaluate lung and heart function over time [6][7].
- Orthopedist: To manage skeletal changes or joint stiffness [8].
- Psychiatrist or Psychologist: To support mental health and behavior [8].
- Social Worker: To assist with school/workplace accommodations, disability benefits, and care coordination.
A Tailored Surveillance Blueprint
International consensus guidelines recommend a comprehensive set of baseline assessments at the time of diagnosis [1]. However, the exact choice and frequency of follow-up tests must be tailored to age, symptoms, cooperation, and treatment status.
- Hearing and Vision: Regular audiometry is vital [9]. Eye exams should include dilated evaluations; specialized imaging like OCT (Optical Coherence Tomography) and ERG (Electroretinography) may be used depending on age and symptoms [5][10].
- Heart and Lungs: Monitoring may involve pulmonary function tests (PFTs) and echocardiography to check for issues like valve disease [6][7].
- Developmental Tracking: Periodic neuropsychological testing helps track learning progress, adaptive skills, and cognitive trajectories [11][12].
- Mental and Behavioral Health: Psychiatric symptoms (like severe anxiety, hallucinations, or mood changes) can emerge, particularly in adolescence and adulthood [13]. If severe agitation, loss of safety, or self-harm thoughts occur, seek urgent emergency psychiatric assessment.
Research and Registries
If participating in enzyme replacement therapy (ERT), you may be invited to join a patient registry, such as the SPARKLE registry [14].
- What it is: Registries collect “real-world” data on the safety, biochemical markers, and long-term effectiveness of treatments [14].
- Your Choice: Participation is strictly voluntary, requires informed consent regarding data privacy, and is not a requirement to receive standard care.
Transitioning to Adult Care
Transitioning from a pediatric to an adult care team is a critical process. Because many adult specialists are unfamiliar with alpha-mannosidosis, this must be a carefully coordinated “handover” [15][1].
- Start Early: Transition discussions should ideally begin in the early teenage years [15].
- Coordinate Care: The pediatric geneticist should provide a comprehensive medical summary and a “surveillance roadmap” to the new adult team [1].
- Support for Independence: Transition planning must also cover supported decision-making, independent living skills, vocational support, and reproductive planning for the future [11][15].
Common questions in this guide
Which specialists are usually involved in alpha-mannosidosis care?
What tests are used for long-term alpha-mannosidosis monitoring?
What mental or behavioral changes need urgent attention?
Is joining the SPARKLE registry required to receive treatment?
When should transition to adult alpha-mannosidosis care begin?
How can we keep alpha-mannosidosis specialists coordinated?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Who is the primary 'care coordinator' on our team who will ensure all these different specialists are communicating with each other?
- 2.Can we review the recommended baseline assessments from the current consensus guidelines and tailor a surveillance plan for our specific needs?
- 3.What specific psychiatric or behavioral signs should we watch for, and what is the emergency plan if severe symptoms arise?
- 4.How do we access genetic counseling, physical therapy, or speech-language support?
- 5.Is participation in a disease registry (like SPARKLE) available to us, and what does the consent and data privacy process involve?
- 6.At what age should we start the formal 'handover' process to adult specialists to ensure there is no gap in treatments or care?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Monitoring and integrated care coordination of patients with alpha-mannosidosis: A global Delphi consensus study.
Guffon N, Burton BK, Ficicioglu C, et al.
Molecular genetics and metabolism 2024; (142(4)):108519 doi:10.1016/j.ymgme.2024.108519.
PMID: 39024860 - 2
Audiological and radiological study of eight polish patients with alpha-mannosidosis.
Iwanicka-Pronicka K, Guzek A, Sarnecki J, Tylki-Szymańska A
International journal of pediatric otorhinolaryngology 2023; (169()):111556 doi:10.1016/j.ijporl.2023.111556.
PMID: 37099947 - 3
Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group.
Guffon N, Tylki-Szymanska A, Borgwardt L, et al.
Molecular genetics and metabolism 2019; (126(4)):470-474 doi:10.1016/j.ymgme.2019.01.024.
PMID: 30792122 - 4
White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis.
Majovska J, Nestrasil I, Paulson A, et al.
Molecular genetics and metabolism 2021; (132(3)):189-197 doi:10.1016/j.ymgme.2020.11.008.
PMID: 33317989 - 5
Early-Onset Retinal Dystrophy in Alpha-Mannosidosis: A Case Report.
Almhmoudi F, Bamusa A, Alrashid A, et al.
Case reports in ophthalmology 2026; (17(1)):471-478 doi:10.1159/000551949.
PMID: 42282242 - 6
Comprehensive cardiopulmonary assessment in α mannosidosis.
Nir V, Bentur L, Tal G, et al.
Pediatric pulmonology 2020; (55(9)):2348-2353 doi:10.1002/ppul.24864.
PMID: 32445542 - 7
Long-term clinical evaluation of patients with alpha-mannosidosis - A multicenter study.
Köse E, Kasapkara ÇS, İnci A, et al.
European journal of medical genetics 2024; (68()):104927 doi:10.1016/j.ejmg.2024.104927.
PMID: 38382588 - 8
Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis.
Bertolini A, Rigoldi M, Cianflone A, et al.
Clinical dysmorphology 2024; (33(1)):1-8 doi:10.1097/MCD.0000000000000474.
PMID: 37791705 - 9
Long-term outcome of patients with alpha-mannosidosis - A single center study.
Lipiński P, Różdżyńska-Świątkowska A, Iwanicka-Pronicka K, et al.
Molecular genetics and metabolism reports 2022; (30()):100826 doi:10.1016/j.ymgmr.2021.100826.
PMID: 35242565 - 10
Retinal and optic nerve degeneration in α-mannosidosis.
Matlach J, Zindel T, Amraoui Y, et al.
Orphanet journal of rare diseases 2018; (13(1)):88 doi:10.1186/s13023-018-0829-z.
PMID: 29859105 - 11
Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis.
Borgwardt L, Thuesen AM, Olsen KJ, et al.
Journal of inherited metabolic disease 2015; (38(6)):1119-27 doi:10.1007/s10545-015-9862-4.
PMID: 26016802 - 12
Intellectual functioning in alpha-mannosidosis.
Cathey SS, Sarasua SM, Simensen R, et al.
JIMD reports 2019; (50(1)):44-49 doi:10.1002/jmd2.12073.
PMID: 31741826 - 13
Retrospective Study of Clinical and Genetic Profiles of Alpha-Mannosidosis Patients From the UAE.
Saad AK, Al-Hammadi T, Al-Ameri S, et al.
JIMD reports 2025; (66(2)):e70001 doi:10.1002/jmd2.70001.
PMID: 39926434 - 14
The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis.
Hennermann JB, Guffon N, Cattaneo F, et al.
Orphanet journal of rare diseases 2020; (15(1)):271 doi:10.1186/s13023-020-01549-8.
PMID: 32993743 - 15
Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy.
Verrecchia E, Sicignano LL, Massaro MG, et al.
Advances in therapy 2021; (38(1)):1-10 doi:10.1007/s12325-020-01574-w.
PMID: 33231860
This page is for informational purposes only and does not constitute medical advice. A metabolic geneticist and your care team should tailor alpha-mannosidosis monitoring, referrals, and emergency plans to your needs.
Get notified when new evidence is published on Alpha-mannosidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.